L-kappa-H-gamma1 (knob) chain anti-DLL3 (1-705) [L-kappa anti-DLL3 (1-214) [V-KAPPA (Homo sapiens IGKV1-17*03 (94.9%) -IGKJ2*01 (100%), CDR-IMGT [6.3.9] (27-32.50-52.89-97)) (1-107) -Homo sapiens IGKC*01 (100%), Km3 A45.1 (153), V101 (191) (108'-214')] -38-mer (GGGGSE GKSSGSGSES KSTEGKSSGS GSESKSTGGGGS) linker (215-252) -H-gamma-1 heavy chain anti-DLL3 (253-705) [VH (Homo sapiens IGHV1-46*01 (92.9%) -(IGHD) -IGHJ6*01 (94.7%), CDR-IMGT [8.8.17] (278-285.303-310.349-365)) (253-376)-Homo sapiens IGHG1*03, G1m3, nG1m1, CH1 R120, CH3 E12, M14, G1v14 CH2 A1.3, A1.2, G1v32 CH3 W22 (knob) (CH1 R120 (473) (377-474), hinge 1-15 (475-489), CH2 L1.3>A (493), L1.2>A (494) (490-599), CH3 E12 (615), M14 (617), T22>W (625) (600-704), CHS K2>del (705)) (377-705)]]; L-lambda6-H-gamma1 (hole) chain anti-CD3E (1-707) [L-lambda6 anti-CD3 (1'-215') [V-LAMBDA Musmus/Homsap (Mus musculus IGLV1*01 (82.3%) -IGLJ1*01 (100%)/Homo sapiens IGLV7-46*01 (76.8%) -IGLJ3*02 (100%), CDR-IMGT [9.3.9] (26'-34'.52'-54'.91'-99')) (1'-109') -Homo sapiens IGLC6*01 (100%) (110'-215')] -38-mer (GGGGSE GKSSGSGSES KSTEGKSSGSGSESKSTGGGGS) linker (216'-253') -H-gamma-1 anti-CD3E (254'-707') [VH Musmus/Homsap (Mus musculus IGHV10-1*02 (92.9%) -(IGHD) -IGHJ3*01 (100%)/Homo sapiens IGHV3-73*01 (87.0%) -(IGHD) -IGHJ6*01 (81.8%) T123>L (373'), S128>A (378'), CDR-IMGT [8.10.16] (279'-286'.304'-313'.352'-367')) (254'-378')-Homo sapiens IGHG1*03, G1m3, nG1m1, CH1 R120, CH3 E12, M14, G1v14 CH2 A1.3, A1.2, G1v33 CH3 S22, A24, V86 (hole), G1v83 CH3 R115, F116 (CH1 R120 (475') (379'-476'), hinge 1-15 (477'-491'), CH2 L1.3>A (495'), L1.2>A (496') (492'-601'), CH3 E12 (617'), M14 (619'), T22>S (627'), L24>A (629'), Y86>V (686'), H115>R (696'), Y116>F (697') (602'-706'), CHS K2>del (707')) (379'-707')]]; dimer (485-487':488-490')-bisdisulfide, produced in Chinese hamster ovary (CHO) cells, cell line CHO-K1, glycoform alfa
Small Cell Lung Carcinoma (SCLC)
